Ticker Hub
ARVN — AI Analysis & Sentiment
5 recent AI-generated analyses for ARVN. Sentiment and confidence insights updated continuously.
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arvinas achieved a pivotal milestone with the FDA approval of VEPPANU, its first PROTAC drug, and secured a licensing agreement with Rigel for its ...
May 12, 2026Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
Arvinas's FDA approval for VEPPANU is a transformative event, validating its PROTAC platform and opening a new revenue stream. While initial commer...
May 1, 2026Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
Arvinas reported strong positive Phase 1 data for ARV-102, significantly de-risking the drug's development for Parkinson's. The negative market rea...
Mar 18, 2026Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Arvinas' upcoming presentation of Phase 1 ARV-102 data for Parkinson's disease is a key event. Positive results could significantly de-risk the pro...
Mar 11, 2026Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Arvinas' improved Q4 2025 financials and extended cash runway, combined with the confirmed June 5, 2026 PDUFA date for vepdegestrant, present a bul...
Feb 24, 2026